Page last updated: 2024-08-21

d-alpha tocopherol and obeticholic acid

d-alpha tocopherol has been researched along with obeticholic acid in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	13 (92.86)	24.3611
2020's	1 (7.14)	2.80

Authors

Authors	Studies
Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S	1
Chaiyakunapruk, N; Chongmelaxme, B; Kowdley, KV; Phisalprapa, P; Saokaew, S; Sawangjit, R; Thakkinstian, A	1
Mintziori, G; Polyzos, SA	1
Dufour, JF; Perazzo, H	1
Jun, DW; Nguyen, MH; Oh, H; Saeed, WK	1
Chan, HL; Chan, WK; Chawla, Y; Chitturi, S; Dan, YY; Duseja, A; Fan, J; Farrell, G; Goh, KL; Hamaguchi, M; Hashimoto, E; Kim, SU; Lesmana, LA; Lin, YC; Liu, CJ; Ni, YH; Sollano, J; Wong, GL; Wong, SK; Wong, VW	1
Bush, H; Golabi, P; Younossi, ZM	1
Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L	1
Grønbæk, H; Heebøll, S; Vilstrup, H	1
Kumar, RB; Mathews, SE; Shukla, AP	1
Brunt, EM; Kleiner, DE; Neuschwander-Tetri, BA; Sanyal, AJ; Wilson, LA	1
Shetty, A; Syn, WK	1
Al-Hamoudi, WK; Al-Judaibi, B; Al-Osaimi, A; Alswat, KA; Alturaify, N; Elsiesy, HA; Fallatah, HI; Qutub, AN	1
Nakajima, A; Ogawa, Y; Okanoue, T; Sumida, Y; Yoneda, M	1

Reviews

13 review(s) available for d-alpha tocopherol and obeticholic acid

Article	Year
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:5 Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E	2015
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine, 2016, Volume: 95, Issue:32 Topics: Antioxidants; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Thiazolidinediones; Treatment Outcome; Vitamin E	2016
Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:14 Topics: Adult; Chenodeoxycholic Acid; Drug Design; Glucagon-Like Peptide 1; Humans; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Thiazolidinediones; Vitamin E	2016
The therapeutic landscape of non-alcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5 Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss	2017
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clinical and molecular hepatology, 2016, Volume: 22, Issue:3 Topics: Biomarkers; Chenodeoxycholic Acid; Clinical Trials as Topic; Fatty Liver; Fibrosis; Humans; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Tomography, X-Ray Computed; Ultrasonography; Vitamin E	2016
The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:1 Topics: Adolescent; Asia; Bariatric Surgery; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Child; Diet; Exercise; Fatty Acids, Omega-3; Gastroenterology; Humans; Liver Neoplasms; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Obesity; Pacific Islands; Practice Guidelines as Topic; Risk; Systematic Reviews as Topic; Thiazolidinediones; Vitamin E	2018
Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinics in liver disease, 2017, Volume: 21, Issue:4 Topics: Antioxidants; Chenodeoxycholic Acid; Cholic Acids; Diet Therapy; Exercise; Free Radical Scavengers; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Vitamin E	2017
Nonalcoholic fatty liver disease: Evolving paradigms. World journal of gastroenterology, 2017, Sep-28, Volume: 23, Issue:36 Topics: Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Diagnostic Imaging; Diet, Reducing; Dyslipidemias; Exercise Therapy; Humans; Hyperuricemia; Hypoglycemic Agents; Liver; Liver Function Tests; Liver Neoplasms; Mass Screening; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Assessment; Risk Factors; Vitamin E	2017
[Treatment of non-alcoholic fatty liver disease]. Ugeskrift for laeger, 2018, Jul-30, Volume: 180, Issue:31 Topics: Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Critical Pathways; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Risk Assessment; Vitamin E	2018
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. Current opinion in endocrinology, diabetes, and obesity, 2018, Volume: 25, Issue:5 Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet; Exercise; Heart Diseases; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Vitamin E	2018
Current treatment options for nonalcoholic fatty liver disease. Current opinion in gastroenterology, 2019, Volume: 35, Issue:3 Topics: Antioxidants; Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Coffee; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Receptors, Cytoplasmic and Nuclear; Sleep; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E	2019
Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi medical journal, 2019, Volume: 40, Issue:6 Topics: Bariatric Surgery; Biomarkers; Biopsy; Chalcones; Chenodeoxycholic Acid; Diagnostic Imaging; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Liver; Liver Transplantation; Mass Screening; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prevalence; Propionates; Thiazolidinediones; Vitamin E	2019
Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:8 Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Vitamin E	2020

Other Studies

1 other study(ies) available for d-alpha tocopherol and obeticholic acid

Article	Year
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology (Baltimore, Md.), 2019, Volume: 70, Issue:2 Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Treatment Outcome; Vitamin E; Vitamins	2019

Article

Year

Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.

Hepatology (Baltimore, Md.), 2019, Volume: 70, Issue:2

Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Treatment Outcome; Vitamin E; Vitamins

2019